MGI Tech and NUS Partner to Launch Multi-Omics DCS Lab in Singapore

The collaboration between MGI Tech and the National University of Singapore (NUS) Department of Pharmacy and Pharmaceutical Sciences represents a pivotal shift in the integration of high-throughput sequencing within academic and industrial pharmaceutical research. By establishing the DCS Lab—an acronym for DNA, Cell, and Spatial—the partnership aims to institutionalize a multi-omics approach that is increasingly becoming the standard for drug discovery and precision medicine. This move is not merely a technical upgrade for NUS; it is a strategic alignment that places Singapore at the center of the next generation of genomic medicine in Southeast Asia.

At the heart of this collaboration is MGI’s proprietary DNBSEQ technology, which has been gaining significant traction globally as a high-accuracy, cost-effective alternative to established sequencing platforms. The 'DCS' strategy is MGI’s comprehensive framework designed to capture biological data at three critical levels: the genomic level (DNA), the single-cell level (Cell), and the tissue-microenvironment level (Spatial). In the context of pharmaceutical sciences, this tripartite data capture allows researchers to understand not just the genetic predisposition to a disease, but how individual cells respond to therapeutic agents and how the spatial arrangement of those cells within a tissue influences drug efficacy and resistance.

“

By establishing the DCS Lab—an acronym for DNA, Cell, and Spatial—the partnership aims to institutionalize a multi-omics approach that is increasingly becoming the standard for drug discovery and precision medicine.

From a market perspective, MGI Tech’s expansion into Singapore’s academic ecosystem is a calculated move to challenge the dominance of Western sequencing giants like Illumina and Pacific Biosciences. By embedding their technology within a premier institution like NUS, MGI ensures a steady pipeline of research validated on their platforms, which often leads to broader adoption across the regional biotech sector. For NUS, the partnership provides students and faculty with hands-on access to cutting-edge automation and spatial transcriptomics tools that are often prohibitively expensive for individual labs to maintain. This synergy is expected to shorten the lead time between basic research and clinical application, particularly in oncology and immunology, where spatial context is paramount.